Top-News
Biotechnologie USA

Scholar Rock Holding Corp Aktie

Aktie
WKN:  A2JMQW ISIN:  US80706P1030 US-Symbol:  SRRK
25,80 €
+0,00 €
0,00%
14:14:18 Uhr
Depot/Watchlist
Aktienanzahl *
93,61 Mio.
Marktkapitalisierung *
2,52 Mrd. €
Streubesitz
-
KGV
-17,50
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 17.12.2024

Scholar Rock Holding Corp News

28.05.25 - Businesswire
Scholar Rock to Present at the Jefferies Global Healthcare Conference
Scholar Rock (NASDAQ: SRRK), a late-​stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) ...
16.05.25 - Businesswire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-​stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular ...
14.05.25 - Businesswire
Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress
Scholar Rock (NASDAQ: SRRK), a late-​stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) ...
07.05.25 - Businesswire
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
Scholar Rock (NASDAQ: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and ...
06.05.25 - Businesswire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-​stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic ...
28.04.25 - Businesswire
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
Scholar Rock (NASDAQ: SRRK), a late-​stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and ...
18.04.25 - Businesswire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-​stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic ...
14.03.25 - Businesswire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-​stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic ...
18.10.24 - wallstreetONLINE Redaktion
Markt verfünffacht sich: Diese 5 Konzerne attackieren Novo, Lilly auf dem lukrativen Adipositas-Markt
Auch wenn alle nur noch über KI reden, der Markt für Gewichtsverlust-​Mittel explodiert regelrecht. Einige Unternehmen haben gute Chancen, den Marktführern gefährlich zu ...
18.10.24 - wallstreetONLINE Redaktion
Neue Medikamente im Rennen: Diese 5 Konzerne attackieren Novo, Lilly auf dem lukrativen Adipositas-Markt
Auch wenn alle nur noch über KI reden, der Markt für Gewichtsverlust-​Mittel explodiert regelrecht. Einige Unternehmen haben gute Chancen, den Marktführern gefährlich zu ...
27.08.24 - wallstreetONLINE Redaktion
25 Milliarden-Dollar-Markt: Viking, Amgen & Co: 6 Aktien, die die 2. Adipositas-Welle dominieren könnten!
Eli Lilly und Novo Nordisk dominieren zwar den Markt für Adipositas-​Medikamente. Die erfolgreichsten Konkurrenten könnten aber bis zu 20 Prozent des lukrativen Marktes erobern, ...
27.08.24 - wallstreetONLINE Redaktion
25 Milliarden-Dollar-Markt: Viking, Amgen & Co: 6 Unternehmen für die nächste Adipositas-Welle!
Eli Lilly und Novo Nordisk dominieren zwar den Markt für Adipositas-​Medikamente. Die erfolgreichsten Konkurrenten könnten aber bis zu 20 Prozent des lukrativen Marktes erobern, ...
12.07.22 - PR Newswire
Thinking about buying stock in Inmode, Evofem Biosciences, Scholar Rock, Verrica Pharmaceuticals, or Indonesia Energy?
Thinking about buying stock in Inmode, Evofem Biosciences, Scholar Rock, Verrica Pharmaceuticals, or Indonesia Energy? PR Newswire
03.08.21 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
19.04.21 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
11.04.21 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
29.10.20 - PR Newswire
Thinking about buying stock in Scholar Rock Holding, Electrameccanica Vehicles, Verastem, Oncolytics Biotech, or Cisco Systems?
Thinking about buying stock in Scholar Rock Holding, Electrameccanica Vehicles, Verastem, Oncolytics Biotech, or Cisco Systems? PR Newswire
28.10.20 - PR Newswire
Thinking about buying stock in Miragen Therapeutics, Nio, Scholar Rock, General Electric, or Boeing?
Thinking about buying stock in Miragen Therapeutics, Nio, Scholar Rock, General Electric, or Boeing? PR Newswire
27.10.20 - PR Newswire
Thinking about buying stock in Scholar Rock Holding, Insignia Systems, Unifi, Southwest Airlines, or Advanced Micro Devices?
Thinking about buying stock in Scholar Rock Holding, Insignia Systems, Unifi, Southwest Airlines, or Advanced Micro Devices? PR Newswire

Newssuche

Videos

newspaper
28.05.25 -2,44%
Technical Trading: Chance auf Verdopplung!
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
OSZAR »